Mechanisms, pathophysiology, and management of obesity
Obesity is prevalent in the US population and contributes significantly to morbidity and
mortality. Treatments include behavioral therapy, pharmacotherapy, and bariatric surgery …
mortality. Treatments include behavioral therapy, pharmacotherapy, and bariatric surgery …
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
The prevalence of obesity in combination with sarcopenia (the age-related loss of muscle
mass and strength or physical function) is increasing in adults aged 65 years and older. A …
mass and strength or physical function) is increasing in adults aged 65 years and older. A …
Clinical application of intermittent fasting for weight loss: progress and future directions
Intermittent fasting diets have become very popular in the past few years, as they can
produce clinically significant weight loss. These diets can be defined, in the simplest of …
produce clinically significant weight loss. These diets can be defined, in the simplest of …
Impact of intermittent fasting on health and disease processes
Humans in modern societies typically consume food at least three times daily, while
laboratory animals are fed ad libitum. Overconsumption of food with such eating patterns …
laboratory animals are fed ad libitum. Overconsumption of food with such eating patterns …
Diet and exercise in the prevention and treatment of type 2 diabetes mellitus
Evidence from observational studies and randomized trials suggests that prediabetes and
type 2 diabetes mellitus (T2DM) can develop in genetically susceptible individuals in …
type 2 diabetes mellitus (T2DM) can develop in genetically susceptible individuals in …
Diabetes and sarcopenic obesity: pathogenesis, diagnosis, and treatments
M Wang, Y Tan, Y Shi, X Wang, Z Liao… - Frontiers in …, 2020 - frontiersin.org
Sarcopenic obesity and diabetes are two increasing health problems worldwide, which both
share many common risk factors, such as aging, and general obesity. The pathogenesis of …
share many common risk factors, such as aging, and general obesity. The pathogenesis of …
Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and mitigation strategies
IJ Neeland, J Linge… - Diabetes, Obesity and …, 2024 - Wiley Online Library
Weight loss induced by glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and dual
glucagon‐like peptide‐1 receptor (GLP‐1R)/glucose‐dependent insulinotropic polypeptide …
glucagon‐like peptide‐1 receptor (GLP‐1R)/glucose‐dependent insulinotropic polypeptide …
Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes: a 2-year non-randomized clinical …
SJ Athinarayanan, RN Adams, SJ Hallberg… - Frontiers in …, 2019 - frontiersin.org
Purpose: Studies on long-term sustainability of low-carbohydrate approaches to treat
diabetes are limited. We previously reported the effectiveness of a novel digitally-monitored …
diabetes are limited. We previously reported the effectiveness of a novel digitally-monitored …
Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial
SB Heymsfield, LA Coleman, R Miller… - JAMA network …, 2021 - jamanetwork.com
Importance Antibody blockade of activin type II receptor (ActRII) signaling stimulates skeletal
muscle growth. Previous clinical studies suggest that ActRII inhibition with the monoclonal …
muscle growth. Previous clinical studies suggest that ActRII inhibition with the monoclonal …
Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
JI Mechanick, WS Butsch, SM Christensen… - Obesity …, 2025 - Wiley Online Library
The rapid and widespread clinical adoption of highly effective incretin‐mimetic drugs (IMDs),
particularly semaglutide and tirzepatide, for the treatment of obesity has outpaced the …
particularly semaglutide and tirzepatide, for the treatment of obesity has outpaced the …